Finally, pirtobrutinib was effective also in patients who had undergone all five available therapies for CLL or SLL—including BTK, BCL2, and PI3K inhibitors, as well as anti-CD20 monoclonal antibodies and chemotherapy. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.